Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been given an average recommendation of “Moderate Buy” by the nine analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $9.43.

Several research firms have issued reports on PYXS. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target (down from $7.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. Royal Bank of Canada restated an “outperform” rating and set a $8.00 price objective (down from $10.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. Stephens began coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 target price for the company. Finally, William Blair downgraded Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st.

Insider Transactions at Pyxis Oncology

In other Pyxis Oncology news, CFO Pamela Ann Connealy purchased 88,850 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were acquired at an average cost of $1.96 per share, with a total value of $174,146.00. Following the completion of the transaction, the chief financial officer now owns 1,199,143 shares in the company, valued at $2,350,320.28. The trade was a 8.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 9.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Intech Investment Management LLC bought a new stake in shares of Pyxis Oncology in the third quarter valued at approximately $55,000. SG Americas Securities LLC bought a new stake in shares of Pyxis Oncology during the 3rd quarter valued at $58,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Pyxis Oncology during the 2nd quarter worth $65,000. MetLife Investment Management LLC increased its position in shares of Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after purchasing an additional 5,484 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new position in Pyxis Oncology in the third quarter valued at about $107,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Stock Down 3.7 %

NASDAQ:PYXS opened at $1.55 on Tuesday. The firm has a market capitalization of $92.17 million, a price-to-earnings ratio of -1.50 and a beta of 1.06. Pyxis Oncology has a twelve month low of $1.49 and a twelve month high of $6.85. The stock’s 50 day moving average price is $2.35 and its two-hundred day moving average price is $3.09.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.